glycoursodeoxycholic-acid and Non-alcoholic-Fatty-Liver-Disease

Farnesoid X receptor (FXR) has emerged as a promising therapeutic target for nonalcoholic steatohepatitis (NASH) because of its tightly interwoven relationship with bile acid homeostasis, inflammation, fibrosis, and glucose and lipid metabolism. Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and

Topics: Animals; Betulinic Acid; Bile Acids and Salts; Ceramides; Fibrosis; Glucose; Inflammasomes; Inflammation; Islet Amyloid Polypeptide; Liver; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pentacyclic Triterpenes; Receptors, Cytoplasmic and Nuclear